CSL (CSLLY) Stock Forecast & Price Target

CSL
Bull Case

Here are some ways that investors could benefit from investing in CSL Limited:

• CSL Limited has recently announced a strategic collaboration with Amazon Web Services to leverage artificial intelligence and cloud technology across its research and clinical development pipeline, a move that could significantly accelerate the company's biopharmaceutical R&D capabilities and enhance its competitive positioning in the global healthcare market.
• The company's CSL Seqirus segment recently secured a strengthened vaccine partnership with the UK Government, which includes the introduction of the world-first aTIVc influenza vaccine and an extended health security pandemic agreement, providing a stable and long-term revenue stream from government contracts and highlighting the segment's leadership in pandemic preparedness.
• CSL Limited has demonstrated strong recent price momentum, with the stock trading at $31.91 as of September 29, 2026, representing a significant recovery from its 52-week low of $16.01 and approaching its 52-week high of $36.29, indicating strong investor confidence and potential for further upside as the stock continues its upward trend.
• Recent analyst actions reflect growing institutional confidence, including an upgrade from Royal Bank of Canada from "hold" to "moderate buy" and a positive report from Ord Minnett, suggesting that the market is beginning to recognize the company's value and potential for growth following its recent earnings report.
• CSL Limited offers a dividend yield of 2.40%, providing investors with a steady income stream while they hold the stock, which is particularly attractive for income-focused investors seeking exposure to the biotechnology sector with a lower beta of 0.61, indicating less volatility compared to the broader market.